Sarit Steinberg

SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis

by

– Funding secured from CF Foundation and current investors for SPL84 Phase 2 study – – Two additional early-stage candidates expected to commence Phase 1-2a studies over the next 12 months – JERUSALEM, April 3, 2024 /PRNewswire/ — SpliSense, a clinical-stage biotechnology company focused on the development of transformative RNA-based therapies for pulmonary diseases including … …

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

by

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares … …

MediWound Reports Positive Results In Head-to-head Comparison Of EscharEx Vs SANTYL

by

(RTTNews) – MediWound Ltd. (MDWD) Monday reported positive results from head-to-head comparison analyses of the company’s lead asset EscharEx for the treatment of chronic wounds to SANTYL ointment. SANTYL was approved by the FDA for debriding chronic dermal ulcers. Results from the secondary analyses of the Phase II ChronEx study showed that EscharEx was superior … …

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

by

AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) — Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. … …